CLL ARC 2017


Keynote Speakers

The Organising Committee is pleased to announce the following confirmed Keynote Speakers:

Dr. Nicholas Chiorazzi

Nicholas ChiorazziDr. Nicholas Chiorazzi is a Professor of Medicine and of Molecular Medicine in the Hofstra North Shore-LIJ School of Medicine and Head of the Karches Center for Chronic Lymphocytic Leukemia Research at The Feinstein Institute for Medical Research (CLL).

Dr. Chiorazzi’s research revolves around understanding the activation and maturation of human-B lymphocytes in health and disease, in partcular CLL. 


Dr. Davide Rossi

fotoDr. Davide Rossi is Head of Service of the Division of Hematology at the Oncology Institute of Southern Switzerland and Group Leader in the Institute of Oncology Research in Bellinzona, Switzerland.

He obtained a Medical Degree magna cum laude from the Amedeo Avogadro University of Eastern Piedmont (2000), then trained in Internal Medicine (board certification in 2005) and obtained a Ph.D. in Clinical and Experimental Medicine (2009).
From 2008 to 2015, he worked as Assistant Professor of Hematology at the Amedeo Avogadro University of Eastern Piedmont, and coordinated an independent clinical and research unit dedicated to lymphoproliferative disorders.

The proponent is financially independent since 2010, managing a total of more than 1.5 million € (ongoing and completed grants). The research topic of the proponent is the molecular pathogenesis and diagnosis of B-cell tumors and translation of biological information into markers for disease diagnosis and prognostication. In this field, original and ground-breaking contributions of the proponent include: i) seminal identification of NOTCH1, SF3B1 and BIRC3 mutations in chronic lymphocytic leukemia and characterization of their clinical role; ii) definition of the molecular bases of high risk chronic lymphocytic leukemia, including refractory and transformed disease; iii) first description of the clinical relevance of small mutated subclones in lymphoproliferaive disorders; iv) seminal identification of NOTCH2, KLF2 and non-canonical NF-κB gene mutations in marginal zone lymphoma.

Overall, the proponent is author of 211 peer reviewed publications (total IF: 1467, total non-self citations: 4323; h-index: 35), including several publications as last senior author.

He was awarded the 2011 young investigator prize for research in the field of lymphomas and leukemias by the Italian National Academy of Sciences, and has established himself as a leader in his field, as documented by a number of honors including chairing sessions at the European Hematology Association (EHA) Congress and Annual Meeting of the American Society of Hematology (ASH), providing educational contributions at the EHA, ASH and ICML meetings, and serving as reviewer for many leading journals, and also for scientific institutions.

Prof. John Seymour

John Seymour_2009 resizeProfessor John Seymour AM is a clinical haematologist and Co-Director of the Division of Cancer Medicine, at the Peter MacCallum Centre, and the Director of the integrated Haematology Unit of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne, Australia.

He received his MB, BS degrees from the University of Melbourne in 1987, completed a translational research fellowship at the MD Anderson Cancer Center in Houston, from which he received their Distinguished Alumnus award in 2011. He also completed PhD studies in the pathobiology of haematopoietic growth factors at the Ludwig Institute for Cancer Research. Professor Seymour is a member of several national and international scientific committees including, Cancer Australia Advisory Groups, the Scientific Advisory Committee for the International Conference on Malignant Lymphoma, Medical Advisory Board of the Lymphoma Coalition, and the Board of Directors of the International Extranodal Lymphoma Study Group.

He served for more than a decade as Executive member and Chairman of the major national clinical trials co-operative group in haematologic malignancies, the Australasian Leukaemia & Lymphoma Group. He is a frequent invited speaker nationally and internationally, is a member of numerous professional societies, and an Editor-in-Chief of Leukemia & Lymphoma and currently on the editorial boards of Blood, and the British Journal of Haematology.

He has authored 18 book chapters, ~450 peer reviewed publications (which have been cited more than 18000 times), and ~650 conference abstracts. Actively involved in a broad range of collaborative research, Professor Seymour has been a chief investigator on grants receiving more than AUD$10.5 million of competitive grant funding in the last 5 years and is the principal investigator on 15 ongoing clinical trials. In 2015 he was awarded Membership of the Order of Australia, and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.